Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Anti-Parkinson's Drugs Market 2018: Analysis & Forecasts (2013-2022) - Major Players Abbvie, Mylan Laboratories, Valeant Pharmaceuticals and Novartis are Profiled - ResearchAndMarkets.com

Research and Markets
Posted on: 12 Mar 18

The "Anti-Parkinson's Drugs: Global Markets to 2022" report has been added to ResearchAndMarkets.com's offering.

This research report categorizes the anti-Parkinson's drugs market by type. Product types include low dopaminergic, dopamine agonists, enzyme inhibitors and other anti-Parkinson's medications.

This report includes:

  • 95 data tables
  • An overview of the global market for anti-Parkinson's drugs and their future demand
  • Analyses of global market trends, with data from 2013-2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Analyses of the major factors and technological advances such as biomarkers, 3D printed drugs, mobile applications and wearable technologies in the monitoring and treatment of Parkinson's disease
  • Discussion of the major segments of the anti-Parkinson's drugs, i.e., dopaminergic drugs, dopamine agonists, enzyme inhibitors and other anti-Parkinson's medications
  • Company profiles of the major players in the market, including AbbVie, Mylan Laboratories, Valeant Pharmaceuticals and Novartis

Key Findings:

  • The global anti-Parkinson's drugs market should reach $5.7 billion by 2022 from $4.2 billion in 2017 at a compound annual growth rate (CAGR) of 6.1%, from 2017 to 2022.
  • Asia Pacific anti-Parkinson's drugs market is expected to grow from $1 billion in 2017 to $1.4 billion in 2022 at a CAGR of 6.4% for the period 2017-2022.
  • North American anti-Parkinson's drugs market is expected to grow from $1.3 billion in 2017 to $1.8 billion in 2022 at a CAGR of 7% for the period 2017-2022.

Companies Mentioned:

  • Abbvie
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • UCB SA

Key Topics Covered:

1 Introduction

2 Summary and Highlights

3 Anti-Parkinson's Drugs Market Characteristics

4 Anti-Parkinson's Drugs Market Size and Growth

5 Anti-Parkinson's Drugs Market Trends and Strategies

6 PESTLE Analysis

7 Anti-Parkinson's Drugs Market Segmentation

8 Anti-Parkinson's Drugs Market Regional and Country Analysis

9 Global Anti-Parkinson's Drugs Market Comparison with Macro Economic Factors

10 Asia-Pacific Anti-Parkinson's Drugs Market

11 Asia-Pacific Anti-Parkinson's Drugs Market: Country Analysis

12 Western Europe Anti-Parkinson's Drugs Market

13 Western Europe Anti-Parkinson's Drugs Market: Country Analysis

14 Eastern Europe Anti-Parkinson's Drugs Market

15 Eastern Europe Anti-Parkinson's Drugs Market: Country Analysis

16 North America Anti-Parkinson's Drugs Market

17 North America Anti-Parkinson's Drugs Market: Country Analysis

18 South America Anti-Parkinson's Drugs Market

19 South America Anti-Parkinson's Drugs Market: Country Analysis

20 Middle East Anti-Parkinson's Drugs Market

21 Africa Anti-Parkinson's Drugs Market

22 Anti-Parkinson's Drugs Market Customer Information

23 Anti-Parkinson's Drugs Market Competitive Landscape

24 Key Mergers and Acquisitions in the Anti-Parkinson's Drugs Market

For more information about this report visit https://www.researchandmarkets.com/research/wz43xb/global?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180312005946/en/

Business Wire
www.businesswire.com

Last updated on: 12/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.